Verimatrix Introduces Embedded DRM to Offer Point-to-point Protection for Online and Offline Video Playback on Any Device
Verimatrix, (Paris:VMX) (Euronext Paris: VMX), formerly known as Inside Secure, a global provider of innovative, customer-friendly cybersecurity solutions that protect video content, endpoint devices, software and applications, has officially introduced Verimatrix Embedded DRM, a new toolkit to support the implementation and integration of embedded video security solutions. Part of the Verimatrix Video Content Authority System (VCAS™), Verimatrix Embedded DRM offers point-to-point protection to address the gaps that occur when video content is delivered beyond the common TV, computer or mobile device connections. For example, premium content, such as Hollywood movies, require a secure connection all the way to a compliant display, such as a video player in an airplane connected to the video displays located in each passenger seat. Failure to encrypt the ‘handshake’ from the player to each display can be a compliance violation and a content protection gap.
Playback devices that are not continuously connected to a license server or otherwise reachable for content authorization and entitlement require mechanisms other than traditional digital rights management (DRM) or conditional access (CA) systems to protect the valuable content they display to viewers. For such applications, the industry has defined two point-to-point protection standards for guaranteed device interoperability: High-bandwidth Digital Content Protection (HDCP) for premium content forwarded to external displays or TV sets and Digital Transmission Content Protection (DTCP) for content protection on the compressed level.
The Verimatrix Embedded DRM toolkit includes customized software libraries for integrated or installable HDCP and DTCP applications and customized HDCP or DTCP source code for compiling directly into embedded systems. Specifically for HDCP, Verimatrix Embedded DRM offers fully flexible HDCP 2.x stacks that address these use cases and meet the content owner requirements – even for 8K premium content. Thanks to Verimatrix’ significant contribution to the standardization of DTCP security, the solution is especially sought after for DTCP software integrations, which allow for secure content storage and local transfer through multiple physical interfaces or via internal data bus within a device.
“Content owners require their content to be protected throughout the entire delivery chain, including download, streaming, storage and playback all the way up to the display, but there are several scenarios in which content cannot be secured by typical DRM or CA systems,” said Martin Bergenwall, SVP of product management at Verimatrix. “Given our deep knowledge and experience of content protection, Verimatrix uniquely offers customized HDCP and DTCP software libraries and source code for playback use cases that go beyond traditional one-way or two-way communications, ensuring that any previous gaps can be closed with state-of-the-art security.’
The number of industries served by Verimatrix Embedded DRM has rapidly expanded as HDCP and DTCP standards continue to be adopted across new markets. To learn more about Verimatrix Embedded DRM and how it provides state-of-the art security and protection, please visit www.verimatrix.com/solutions/embedded-drm.
About Verimatrix
Verimatrix (Euronext Paris: VMX), formerly known as Inside Secure, is a global provider of innovative, customer-friendly cybersecurity solutions that protect content, devices, software and applications across multiple markets. Many of the world’s largest service providers and leading innovators trust Verimatrix to protect systems that people depend on every day. With more than 20 years of experience and the top minds in the industry, the company is uniquely positioned to understand and proactively anticipate security and business challenges for customers. Verimatrix partners to provide innovative, customer-friendly solutions that are cost-effective, easy to deploy and supported with responsive customer service teams based worldwide. To learn more, visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005452/en/
Contact information
Investor and media contacts
Investor Relations
Richard Vacher Detournière
Directeur général – Directeur financier
+33 (0)4 42 905 905
finance@verimatrix.com
Contact Media
Kelly Foster
+1 619 224 1261
kfoster@verimatrix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom